Merck Joins KRAS Stampede In Deal With Otsuka Affiliates
Executive Summary
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
You may also be interested in...
Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
Biopharma Quarterly Dealmaking Statistics, Q1 2020
During Q1, biopharmas brought in an aggregate $13.8bn in financing. M&A value reached $6.9bn, the majority from Gilead Sciences $4.9bn purchase of immuno-oncology firm Forty Seven. Alliances fetched $35bn in potential deal value, dominated by many Big Pharma tie-ups led by a $4bn discovery and development collaboration between AstraZeneca and Silence Therapeutics for siRNA therapeutics.
Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
Need a specific report? 1000+ reports available
Buy Reports